A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic

► Prospective observational study conducted to meet post marketing commitments for Celtura. ► 3989 subjects followed for occurrence of adverse events following vaccination with Celtura. ► No concern was raised regarding the occurrence of adverse events of special interest. ► Supports good safety profile of MF59 adjuvanted cell culture-derived influenza H1N1 vaccine.